## Krisztina Bencsik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3065751/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Hungarian validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery and the correlation of cognitive impairment with fatigue and quality of life. Multiple Sclerosis and Related Disorders, 2015, 4, 499-504.	2.0	67
2	The Prevalence of Multiple Sclerosis, Distribution of Clinical Forms of the Disease and Functional Status of Patients in Csongrád County, Hungary. European Neurology, 2001, 46, 206-209.	1.4	37
3	Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives. Cells, 2020, 9, 1564.	4.1	36
4	Contributing factors to healthâ€related quality of life in multiple sclerosis. Brain and Behavior, 2019, 9, e01466.	2.2	34
5	Prevalence of cognitive impairment among Hungarian patients with relapsing-remitting multiple sclerosis and clinically isolated syndrome. Multiple Sclerosis and Related Disorders, 2017, 17, 57-62.	2.0	28
6	The Contribution of Various MRI Parameters to Clinical and Cognitive Disability in Multiple Sclerosis. Frontiers in Neurology, 2018, 9, 1172.	2.4	23
7	Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy—Kynurenines Are Important Players. Molecules, 2021, 26, 3423.	3.8	20
8	Gray Matter Atrophy Is Primarily Related to Demyelination of Lesions in Multiple Sclerosis: A Diffusion Tensor Imaging MRI Study. Frontiers in Neuroanatomy, 2017, 11, 23.	1.7	19
9	Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature. Journal of Clinical Neuroscience, 2018, 48, 7-10.	1.5	19
10	The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary. Multiple Sclerosis and Related Disorders, 2016, 7, 26-32.	2.0	18
11	Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series. Neurological Sciences, 2017, 38, 481-483.	1.9	18
12	Validation of the Fatigue Impact Scale in Hungarian patients with multiple sclerosis. Quality of Life Research, 2011, 20, 301-306.	3.1	17
13	Proteomics in Multiple Sclerosis: The Perspective of the Clinician. International Journal of Molecular Sciences, 2022, 23, 5162.	4.1	15
14	Epidemiology of multiple sclerosis in Central Europe, update from Hungary. Brain and Behavior, 2020, 10, e01598.	2.2	13
15	Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013. Journal of the Neurological Sciences, 2016, 367, 329-332.	0.6	12
16	Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters, 2017, 651, 128-133.	2.1	9
17	Altered brain network function during attention-modulated visual processing in multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852095836.	3.0	9
18	Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations. International Journal of Molecular Sciences, 2022, 23, 3383.	4.1	9

**KRISZTINA BENCSIK** 

#	Article	IF	CITATIONS
19	Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine. Mini-Reviews in Medicinal Chemistry, 2020, 20, 269-285.	2.4	6
20	Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study. Pharmaceuticals, 2022, 15, 598.	3.8	6
21	The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary. PLoS ONE, 2022, 17, e0267346.	2.5	5
22	Pediatric multiple sclerosis and fulminant disease course: Features and approaches to treatment – A case report and review of the literature. Journal of Clinical Neuroscience, 2018, 53, 13-19.	1.5	4
23	Two Classes of T1 Hypointense Lesions in Multiple Sclerosis With Different Clinical Relevance. Frontiers in Neurology, 2021, 12, 619135.	2.4	4
24	Do Hungarian multiple sclerosis care units fulfil international criteria?. PLoS ONE, 2022, 17, e0264328.	2.5	4
25	Chemokine receptor V Δ32 deletion in multiple sclerosis patients in Csongrád County in Hungary and the North-Bácska region in Serbia. Human Immunology, 2015, 76, 59-64.	2.4	3
26	Gray Matter Atrophy to Explain Subclinical Oculomotor Deficit in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 589.	2.4	3
27	Functional Connectivity Lateralisation Shift of Resting State Networks is Linked to Visuospatial Memory and White Matter Microstructure in Relapsing–Remitting Multiple Sclerosis. Brain Topography, 2022, 35, 268-275.	1.8	3
28	Short Communication: Treatment of Relapsing-Remitting Multiple Sclerosis 96 Patients with IFN-β1b: Results of a 6-Year Follow-Up. Journal of Interferon and Cytokine Research, 2006, 26, 96-100.	1.2	1
29	Connection between microstructural alterations detected by diffusion MRI and cognitive dysfunction in MS: A model-free analysis approach. Multiple Sclerosis and Related Disorders, 2022, 57, 103442.	2.0	1
	Unilateral thalamic infarction causing downward gaze palsy in a patient with uncorrected tetralogy of Fallot: a case report = A lefelé tekintés bénulÃ:sÃ:t okozó egyoldali thalamusinfarktus		

30 or ranot: a case report = A letelA© tekintA©s bA©nulAjsAjt okozA<sup>3</sup> egyoldali thalamusinfarktus
Fallot-tetralÃ<sup>3</sup>gia nem korrigÃjlt formÃjjÃjval élÅ' felnÅ'ttnél: esetismertetés. Ideggyogyaszati Szemle, 2016,<sup>0.7</sup>
69, 415-419.